Novartis completes acquisition of Brandon Capital-backed Myricx Bio

PUBT · 1d ago
Novartis completes acquisition of Brandon Capital-backed Myricx Bio
  • Brandon Capital portfolio company Myricx Bio became an indirect, wholly owned subsidiary of Novartis on Aug. 28, 2026.
  • The deal gives Novartis control of Myricx Bio’s N-myristoyltransferase inhibitor payload platform for antibody-drug conjugates.
  • Novartis plans to advance NMTi-ADCs across multiple solid tumor settings, targeting improved efficacy with better tolerability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brandon Capital Partners Pty Ltd published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.